Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.48 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | SIK1 | P57059 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.38 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PAICS | P22234 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16721200 | 0.94 | BRD4 (0.56) | BRD4EEDPRKAB2ABL1CSF1R | |
| SCHEMBL16722560 | 0.92 | BRD4 (0.55) | BRD4EEDPRKAB2ABL1CSF1R | |
| SCHEMBL16722354 | 0.90 | BRD4 (0.47) | BRD4PDK2PAICS | |
| SCHEMBL16722546 | 0.88 | BRD4 (0.47) | BRD4PDK2 | |
| SCHEMBL16721676 | 0.87 | BRD4 (0.49) | BRD4PRKAB2ABL1CSF1RLYN | |
| SCHEMBL16722317 | 0.86 | BRD4 (0.51) | BRD4PAICS | |
| SCHEMBL16721827 | 0.85 | BRD4 (0.45) | BRD4PAICS | |
| SCHEMBL16721579 | 0.85 | BRD4 (0.48) | BRD4PRKAB2ABL1CSF1RLYN | |
| SCHEMBL16722196 | 0.85 | BRD4 (0.48) | BRD4 | |
| SCHEMBL16721136 | 0.85 | BRD4 (0.48) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071205-B1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-05 | — | — | EP | claimed |
| US-20180312524-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-01 | — | — | US | claimed |
| EP-3071205-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | Forma Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | claimed |
| US-9422281-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | claimed |
| WO-2015074081-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | claimed |
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-3071205-B1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190330233-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180312524-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-01 | — | — | US | disclosed |
| EP-3071205-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | Forma Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9422281-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2015074081-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330233-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885EED 408/4885PRKAB2 3381/4885 |
| US-10703764-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885EED 408/4885PRKAB2 3381/4885 |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885EED 408/4885PRKAB2 3381/4885 |
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885EED 408/4885PRKAB2 3381/4885 |
| US-20180312524-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885EED 408/4885PRKAB2 3381/4885 |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885EED 408/4885PRKAB2 3381/4885 |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885EED 408/4885PRKAB2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.